For research use only. Not for therapeutic Use.
AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. AG-636 has strong anticancer effects[1].
AG-636 has strong growth-inhibitory activity in cancer cell lines of hematologic versus solid tumor origin[1].
AG-636 (10-100 mg/kg ; oral gavage; twice daily; for 14 days) treatment results in robust tumor growth inhibition in the OCILY19 DLBCL tumor xenograft model[1].
| Catalog Number | I021507 |
| CAS Number | 1623416-31-8 |
| Synonyms | 3-methyl-6-[4-(2-methylphenyl)phenyl]benzotriazole-4-carboxylic acid |
| Molecular Formula | C21H17N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H17N3O2/c1-13-5-3-4-6-17(13)15-9-7-14(8-10-15)16-11-18(21(25)26)20-19(12-16)22-23-24(20)2/h3-12H,1-2H3,(H,25,26) |
| InChIKey | GSBZRCGZLMBSNY-UHFFFAOYSA-N |
| SMILES | CC1=CC=CC=C1C2=CC=C(C=C2)C3=CC(=C4C(=C3)N=NN4C)C(=O)O |
| Reference | [1]. Gabrielle McDonald, et al. Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase. Mol Cancer Ther. 2020 Dec;19(12):2502-2515. |
